Roche touts ‘best-in-disease’ potential for anti-hypertensive zilebesiran
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.
List view / Grid view
While AstraZeneca’s first-in-class candidate baxdrostat marks phase III hypertension win at ESC 2025.
For a transaction value of nearly $2b, AstraZeneca is set to acquire CinCor Pharma, Inc., including rights to hypertension drug baxdrostat.
EPR rounds up results from several key clinical trials on therapies for hypertension and heart failure presented at the American Heart Association’s Scientific Sessions 2022.
Hypertension drug-resistance could no longer be a problem for patients, according to a study on Baxdrostat, shown to lower blood pressure.